Lucia L Lam
Overview
Explore the profile of Lucia L Lam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1968
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seiler R, Ashab H, Erho N, van Rhijn B, Winters B, Douglas J, et al.
Eur Urol
. 2017 Apr;
72(4):544-554.
PMID: 28390739
Background: An early report on the molecular subtyping of muscle-invasive bladder cancer (MIBC) by gene expression suggested that response to neoadjuvant chemotherapy (NAC) varies by subtype. Objective: To investigate the...
2.
Seiler R, Lam L, Erho N, Takhar M, Mitra A, Buerki C, et al.
J Urol
. 2016 Apr;
196(4):1036-41.
PMID: 27105761
Purpose: Clinical staging in patients with muscle invasive bladder cancer misses up to 25% of lymph node metastasis. These patients are at high risk for disease recurrence and improved clinical...
3.
Freedland S, Choeurng V, Howard L, de Hoedt A, du Plessis M, Yousefi K, et al.
Eur Urol
. 2016 Jan;
70(4):588-596.
PMID: 26806658
Background: Despite salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) after radical prostatectomy (RP), some patients still progress to metastases. Identifying these men would allow them to undergo systemic...
4.
Ross A, Johnson M, Yousefi K, Davicioni E, Netto G, Marchionni L, et al.
Eur Urol
. 2015 Jun;
69(1):157-65.
PMID: 26058959
Background: Radical prostatectomy (RP) is a primary treatment option for men with intermediate- and high-risk prostate cancer. Although many are effectively cured with local therapy alone, these men are by...
5.
Lalonde E, Ishkanian A, Sykes J, Fraser M, Ross-Adams H, Erho N, et al.
Lancet Oncol
. 2014 Dec;
15(13):1521-1532.
PMID: 25456371
Background: Clinical prognostic groupings for localised prostate cancers are imprecise, with 30-50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We aimed to test combined genomic and microenvironmental indices...
6.
Mitra A, Lam L, Ghadessi M, Erho N, Vergara I, Alshalalfa M, et al.
J Natl Cancer Inst
. 2014 Oct;
106(11).
PMID: 25344601
Background: Nearly half of muscle-invasive bladder cancer patients succumb to their disease following cystectomy. Selecting candidates for adjuvant therapy is currently based on clinical parameters with limited predictive power. This...
7.
Cotton A, Chen C, Lam L, Wasserman W, Kobor M, Brown C
Hum Mol Genet
. 2013 Oct;
23(5):1211-23.
PMID: 24158853
X-chromosome inactivation results in dosage equivalence between the X chromosome in males and females; however, over 15% of human X-linked genes escape silencing and these genes are enriched on the...
8.
Karnes R, Bergstralh E, Davicioni E, Ghadessi M, Buerki C, Mitra A, et al.
J Urol
. 2013 Jun;
190(6):2047-53.
PMID: 23770138
Purpose: Patients with locally advanced prostate cancer after radical prostatectomy are candidates for secondary therapy. However, this higher risk population is heterogeneous. Many cases do not metastasize even when conservatively...
9.
Lam L, Emberly E, Fraser H, Neumann S, Chen E, Miller G, et al.
Proc Natl Acad Sci U S A
. 2013 May;
110(14):E1247.
PMID: 23667927
No abstract available.
10.
Price M, Cotton A, Lam L, Farre P, Emberly E, Brown C, et al.
Epigenetics Chromatin
. 2013 Mar;
6(1):4.
PMID: 23452981
Background: Measurement of genome-wide DNA methylation (DNAm) has become an important avenue for investigating potential physiologically-relevant epigenetic changes. Illumina Infinium (Illumina, San Diego, CA, USA) is a commercially available microarray...